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Abstract: Step counts and oxygen consumption have yet to be reported during the 2-min walk
test (2MWT) test in persons with lower-limb amputations (LLA). The purpose of this study was to
determine step counts and oxygen consumption during the 2MWT in LLA. Thirty-five men and
women walked for two minutes as quickly as possible while wearing activity monitors (ActiGraph
Link on the wrist (LW) and ankle (LA), Garmin vivofit®3 on the wrist (VW) and ankle (VA), and a
modus StepWatch on the ankle (SA), and a portable oxygen analyzer. The StepWatch on the ankle
(SA) and the vivofit3 on the wrist (VW) had the least error and best accuracy of the activity monitors
studied. While there were no significant differences in distance walked, oxygen consumption (VO2)
or heart rate (HR) between sexes or level of amputation (p > 0.05), females took significantly more
steps than males (p = 0.034), and those with unilateral transfemoral amputations took significantly
fewer steps than those with unilateral transtibial amputations (p = 0.023). The VW and SA provided
the most accurate step counts among the activity monitors and were not significantly different than
hand counts. Oxygen consumption for all participants during the 2MWT was 8.9 ± 2.9 mL/kg/min,
which is lower than moderate-intensity activity. While some may argue that steady-state activity has
not yet been reached in the 2MWT, it may also be possible participants are not walking as fast as they
can, thereby misclassifying their performance to a lower standard.
Keywords: lower-limb prosthesis; wearable activity monitors; metabolic cost; 2MWT; oxygen con-
sumption; actigraphy; accelerometer
1. Introduction
In the United States there are nearly 2 million individuals living with limb loss, and
this number is estimated to nearly double by 2050 [1]. For those undergoing amputation as
a result of diabetes, there is a five-year mortality rate of nearly 77% [2]. Reports from around
the globe have indicated a decline in the rate of major limb amputations [3–6]. This trend
is a result of improved education for patients and clinicians and therapeutic footwear [7].
Still, five-year mortality rates for those undergoing major nontraumatic amputations have
shown to range from 52% to 80% [8], and some have reported amputation rates nearly two
times higher for males than females irrespective of the cause of amputation [9].
Fortunately, persons with lower-limb loss can often be fit, and they can begin ambulat-
ing in a prosthesis within a year [10]. A successful outcome for clinicians and patients alike
is viewed as a return to functional independence and restoration of quality of life (QoL).
From a prosthesis user’s perspective, mobility in a prosthesis appears to be the single most
important contributing factor to QoL [11–14]. Numerous modern prosthetic technologies,
ranging from roll-on liners [15–17] and prosthetic sockets [18–22] to powered knee and
feet [23–25], are available for the prosthetist to provide to a suitable candidate. However,
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these technologies can incur substantial healthcare costs to the user and third-party payers.
Outcome measurements and wearable technologies help evaluate the value of prosthetic
treatment, but mainstream adoption still appears to be a challenge [26,27].
Performance-based assessments of walking performance and speed are suitable mea-
sures as they relate to overall functional capacity [28]. The 2-min walk test (2MWT) is
widely recognized as a reliable and responsive measure for determining prosthesis user
walking ability [29]. The standard error of measurement (SEM) and minimum detectable
change (MDC), both of which provide important clinically relevant indices, have also
been determined for the 2MWT in prosthesis users [30]. In addition, the 2MWT has been
chosen as the basis for the determination of wearable accuracy in community-dwelling
older persons and those having experience stroke [31,32]. Wearable technology, such as
pedometers and accelerometers, can measure walking performance outside the confines of
the clinic in real-world patient settings [33,34]. The breadth of activity monitoring schol-
arship has evaluated the activity of users wearing various prosthetic componentry [35],
and the ActiGraph™ GTX3X+, a commercial-grade monitor, has shown promising results
at estimating energy expenditure in lower limb prosthesis users depending on where the
device is placed [36]. Still, for consumer and commercial grade wearables to be useful,
their accuracy must be determined. Underestimation of step counts has been observed
by some consumer-grade activity monitors at faster walking speeds, such as the Garmin
Vivosmart HR® [37], but this device may still be useful in a population that experiences
slower walking speeds.
More recently, the 2MWT has been shown to be predictive of the much longer 6-min
walk test (6MWT) [38] and has been encouraged as an easier alternative [30–41]. However,
even though both tests encourage the patient to cover as much distance as possible, only
the 6MWT has evaluated and classified submaximal aerobic capacity [42–44]. Previous
studies in elderly persons observed oxygen uptake (VO2) during the 6MWT that reached
moderate-intensity physical activity levels [45,46], and in patients with heart failure, VO2
can even approach intense physical activity levels [47]. Using the 2MWT as a proxy of
aerobic capacity could be erroneous, as the time needed to reach physiological steady-state
or moderate-intensity is typically above three minutes [48]. The 6MWT provides ample
time for individuals to reach steady-state physiology. In contrast, the 2MWT may be too
short in duration to understand aerobic capacity, but this shorter duration may be better
tolerated by lower limb amputees. To the knowledge of the authors, there is a dearth
of data exploring VO2 during 2MWT in persons with lower-limb amputations (LLA).
Measurement of VO2 during the 2MWT using portable technology in LLA could help
elucidate physiological effort required during this outcome measure.
To date, no studies have quantified step count and oxygen uptake during the 2MWT
in LLA. This information could be used to affect rehabilitation objectives and prosthesis
provision. The purpose of this study, therefore, was to (1) determine step count and step
count accuracy of various activity monitors and (2) oxygen consumption during the 2MWT
in LLA.
2. Materials and Methods
2.1. Participants
This cross-sectional study was approved by the Texas A&M University-San Antonio
Institutional Review Board (Log #2017-37) and performed according to the guidelines of the
Declaration of Helsinki. Participants were recruited through public peer-support groups in
San Antonio, Texas, and surrounding communities between August 2018–February 2020.
Data collection was performed after participants consented to the study. A convenient
sample of 35 participants (Table 1) signed an informed consent before any data collection.
For eligibility criteria in the current investigation, we considered participants with an
amputation at the tibial or femoral level on one or both sides. On the contrary, participants
were excluded if they relied on any assistive walking devices, such as a wheelchair, crutches,
etc. All participants were classified as community ambulators capable of varying cadence
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according to the Medicare Functional Classification Level (MFCL K3). Participants did
not have any uncontrolled cardiovascular or respiratory conditions which would have
affected their study performance. Bodyweight was measured using a digital weight scale
(Detecto SlimPRO, Webb City, MO, USA) while wearing prostheses and shoes, and height
was measured with a stadiometer (Seca 213, Hamburg, Germany).
Table 1. Participant Characteristics.
Characteristics Total (N = 35) Male (n = 19) Female (n = 16)
Age (years) 48.5 ± 14.8 52.2 ± 14.6 46.5 ± 15.1
Height (cm) 171.0 ± 8.5 176.5 ± 5.7 164.4 ± 6.2
Weight (kg) 86.0 ± 24.6 99.1 ± 21.8 70.5 ± 18.0
BMI (kg/m2) 29.2 ± 7.2 31.8 ± 6.9 26.1 ± 6.3
Amputation Duration (y) 9.5 ± 8.7 7.4 ± 5.4 12.1 ± 11.1
Classification
Right Transtibial 15 11 4
Left Transtibial 8 3 5
Right Transfemoral 2 1 1
Left Transfemoral 7 4 3
Bilateral Transtibial 3 0 3
Data are expressed as mean ± SD. Note: cm; centimeters, kg; kilograms, m2; meters square, y; year.
Stride length was calculated by having meter sticks placed on the ground of the
walkway and having participants stand behind a line approximately one meter behind
the sticks. An iPad camera using the slow-motion video setting was then turned on, and
participants were instructed to walk at a self-selected pace that was not too fast and not too
slow, just parallel to the meter sticks. The video was then reviewed, and stride length was
measured on the prosthesis side from the first heel contact to the next heel contact on the
same leg.
2.2. Activity Monitor Placement
Participants were then fit with an ActiGraph™ GT9X Link (Pensacola, FL, USA) and
Garmin vivofit® 3 (Olathe, Kansas, USA) on the non-dominant wrist with the Link just
distal to the vivofit3. A Link and vivofit3 were also fit around the distal prosthesis just
above the ankle, with the Link also distal to the vivofit3. Finally, a Modus StepWatch 4
(Edmonds, WA, USA) was also fit inferior to the Link. In the case of those with bilateral
amputations, monitors were fit on the non-dominant leg (Figure 1).
While only step counts were of interest, the monitors were still activated using gender,
height, weight, and age. The Link monitor was also activated with the location of placement,
such as right or left wrist and ankle, with a sample rate of 50 Hz. The Link watch face was
also enabled to see step counts. Stride length was entered into the StepWatch application
on an iPad, and the “quick” setup was used, which only required height and a yes or no
response of two questions: (1) Does the participant frequently run or jog and (2) does the
participant show an impaired gait? A 10-stride calibration was then performed to complete
the setup.
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Figure 1. Placement of the activity monitors at the non-dominant wrist and prosthetic ankle.
2.3. Metabolic Analyzer
Participants were then fit with a Polar heart rate chest strap and a Cosmed K5 portable
metabolic analyzer (Rome, Italy), which was calibrated following the manufacturer’s
guidelines. Participants sat for three minutes, during which time the 2-min walk test was
explained and demonstrated. Participants were told to walk as fast as possible but to do so
safely while covering as much ground as possible. Participants were also told they were
allowed to stop but that time would continue and that they were to resume when able to
do so. At the end of the walk, they were instructed to stop as quickly as possible and to
remain still.
2.4. Two-Minute Walk Test
After the three minutes, participants stood behind a start line taped on the floor, and
the activity monitors were recorded for pre-step counts, the metabolic analyzer was marked
to indicate the start of the walk, and the walk began on a count-down with “three, two,
one, go.” Two investigators followed the participant to avoid pacing, one keeping time
and filming the lower body and the other with a measuring wheel. Participants walked
along a flat, level flooring inside a hallway and made a right turn approximately every
50 m. A one-minute notification was given halfway through the test. At the end of the
test, a notification of “five, four, three, two, one, stop” was given. The metabolic analyzer
was again marked to indicate the end of the walk, and a rating of perceived exertion
(Borg’s 6–20 scale) was recorded. Participants remained still for approximately one minute,
after which post-step counts were recorded from the monitors. Distance walked was then
recorded, and at a later time, actual step counts (AC) were reviewed and recorded by two
investigators using a Grainger standard hand tally counter (Lake Forest, IL, USA). In case
AC were not equal between the two investigators, the film was again reviewed by both on
separate occasions until AC were determined.
2.5. Statistical Analysis
All data were analyzed with IBM SPSS v25 (Chicago, IL, USA). Descriptive statistics
were used to report step counts, walking speed, oxygen consumption (VO2), heart rate
(HR), and rating of perceived exertion (RPE) during the 2-min walk test. Independent
t-tests were used to make comparisons between sex, and one-way analysis of variance
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(ANOVA) was used to compare between levels of amputation. For comparisons of the
level of amputation, those with right and left transtibial amputations were combined to the
unilateral transtibial group, right and left transfemoral amputations were combined to the
unilateral transfemoral group and bilateral transtibial for the third independent group. The
Bonferroni technique was used to control for type I error during post hoc testing. Alpha
was set at 0.05 for all tests.
Repeated-measures analyses of variance (RMANOVA) were used to determine differ-
ences between actual step count (AC), Link worn on the wrist (LW), vivofit3 worn on the
wrist (VW), Link worn on the ankle (LA), vivofit3 worn on the ankle (VA), and StepWatch
worn on the ankle (SA), with Alpha set at 0.05, and partial eta squared reported as the
estimate of effect size. The Bonferroni technique was applied for the confidence interval
adjustment when examining the pairwise comparisons among the AC and the monitors
to maintain significance at 0.05. Cohen’s d with the pooled SD was used to compute the
effect size between the AC and monitor counts. Single measure intraclass correlation
coefficient (ICC) from a two-way random effects ANOVA was used to assess the agree-
ment between AC and monitor counts, with 0.90 or greater considered high agreement;
0.80 to 0.89, moderate agreement; and 0.79 or lower, low agreement [49]. Bland–Altman
plots of AC versus monitor counts were used to provide an indication of overrepresenta-
tion/underrepresentation of steps (error) and agreement between the monitors [50]. Error
scores of zero indicate no difference between the AC registered by the monitors. Scores
below zero indicate an overestimation by the monitors, and scores above zero indicate an
underestimation by the monitors. These plots illustrate the variability in monitor steps
while allowing for the mean difference score and the 95% limits of agreement to be shown.
Percent error was calculated as ([steps detected by monitor-AC]/AC) × 100.
3. Results
3.1. Step Count and Metabolic Variables
Mean step counts, distance walked, VO2, HR, and RPE during the 2-min walk test
are presented in Table 2. While there were no significant differences in walking speed
between sexes, females took approximately 17 more steps than males, t(33) = 2.2, p = 0.034,
resulting in a significantly greater cadence. Oxygen consumption, HR, and RPE were not
significantly different between males and females.
Table 2. Two-minute walk test outcome variables by sex.
Parameter Total (N = 35) Males (n = 19) Females (n = 16)
Steps 220.0 ± 24.3 212.1 ± 19.9 229.4 ± 26.2 *
Cadence (steps/m) 110.0 ± 12.1 106.0 ± 9.9 114.7 ± 13.1 *
Distance Walked (m) 147.02 ± 25.9 144.4 ± 24.6 150.2 ± 27.8
Speed (m/min) 73.5 ± 12.9 72.2 ± 12.3 75.1 ± 13.8
VO2 (mL/kg/min) 8.9 ± 2.9 8.3 ± 1.6 9.7 ± 3.9
Heart Rate (b/min) 102.8 ± 19.4 98.5 ± 18.7 108.1 ± 19.6
RPE 10.1 ± 2.2 9.7 ± 1.9 10.5 ± 2.4
Data are expressed as mean ± SD. RPE = rating of perceived exertion using Borg’s 6–20 scale, where lower ratings
represent lower perceived exertion. * Significantly greater than males. Note: m; meters, mL; milliliters, VO2;
volume of oxygen, kg; kilograms, b; beats, RPE; rating of perceived exertion.
There were no significant differences in distance walked, VO2, HR, and RPE between
amputation levels, p > 0.05. Step counts, however, were significantly different between
groups (F(2,32) = 4.5, p = 0.020), and post hoc tests indicated those with unilateral transtibial
amputations had significantly greater cadence than those with unilateral transfemoral
amputations, p = 0.023, Table 3.
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Steps 228.0 ± 21.9 203.2 ± 23.2 * 209 ± 19.9
Cadence (steps/m) 114.0 ± 10.9 101.6 ± 11.6 * 104.5 ± 9.9
Distance Walked (m) 154.1 ± 27.6 136.6 ± 16.0 124.0 ± 10.2
Speed (m/min) 77.0 ± 13.8 68.3 ± 8.0 62.0 ± 5.1
VO2 (mL/kg/min) 8.5 ± 3.1 10.6 ± 2.7 8.0 ± 1.2
Heart Rate (b/min) 103.1 ± 18.9 103.7 ± 24.3 96.9 ± 10.4
RPE 10.1 ± 2.2 10.0 ± 2.5 10.0 ± 1.7
Data are expressed as mean ± SD. RPE = rating of perceived exertion using Borg’s 6–20 scale, where lower ratings
represent lower perceived exertion. * Significantly greater than Unilateral Transtibial. Note: m; meters, VO2;
volume of oxygen, mL; milliliters, kg; kilograms, b; beats, RPE: rating of perceived exertion.
3.2. Activity Monitors
The RMANOVA indicated significant differences among the step counts during the
2-min walk test, F(5, 29) = 4.9, p = 0.002, ηp2 = 0.459. Pairwise comparisons indicated LW
was significantly lower than AC (p = 0.048, d = 0.82) and VA was significantly higher than
AC (p = 0.033, d = 0.72). VW (p = 1.0, d = 0.11), LA (p = 0.582, d = 0.56), and SA (p = 0.996,
d = 0.09) were not significantly different than AC. Agreement with AC among the monitors
during the 2-min walk was highest with SA and VW, while all others indicated very low
agreement. Step counts and intraclass correlation coefficients with 95% confidence limits
are presented in Table 4.
Table 4. Activity monitor step counts.
Parameter Step Counts (N = 35) ICC 95% Confidence Interval
AC 220.0 ± 24.3 —– ———-
LW 165.7 ± 89.4 * 0.005 −0.256 to 0.299
VW 222.8 ± 24.6 0.895 0.802 to 0.945
LA 198.5 ± 47.9 0.111 −0.202 to 0.418
VA 253.2 ± 59.8 * 0.122 −0.141 to 0.398
SA 222.4 ± 23.2 0.967 0.929 to 0.984
Step counts are expressed as mean ± SD. AC is actual counts, LW is Link on the wrist, VW vivofit3 on the wrist,
LA is Link on the ankle, VA is vivofit3 on the ankle, SA is StepWatch on the ankle. * Significantly different from
AC (p < 0.05). ICC = intraclass correlation coefficients.
Bland–Altman plots are consistent with the ICCs, indicating VW and SA had the
tightest limits of agreement (dashed lines representing 2 SD) and least error (closest to zero)
compared to LW, LA, and VA (Figure 2).
Percent error was the least in SA, followed by VW, and the greatest in LW (Table 5).
Table 5. Error scores of activity monitors.
Parameter Percent Error Mean Error 95% Limit of Agreement
LW −24.6 54.2 ± 94.5 −134.8 to 243.3
VW 1.3 −2.8 ± 11.0 −24.9 to 19.2
LA −9.1 20.1 ± 54.4 −88.7 to 128.9
VA 15.1 −33.2 ± 59.5 −152.2 to 85.8
SA 1.1 −2.3 ± 5.7 −13.8 to 9.1
AC is actual counts, LW is Link on the wrist, VW vivofit3 on the wrist, LA is Link on the ankle, VA is vivofit3 on
the ankle, SA is StepWatch on the ankle.
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Figure 2. The Garmin vivofit3 worn on the wrist (B) and the modus StepWatch worn on the prostheses ankle (E) had the
least error and tightest limits of agreement compared to the ActiGraph Link worn on the wrist (A) and ankle (C), and the
vivofit3 worn on the ankle (D).
4. Discussion
In this study, we measured the step counts in LLA during a 2-min walk test using
different activity monitors while oxygen consumption was measured. The SA and VW
were the most accurate devices, and oxygen consumption for all participants during the
2MWT was lower than what is considered moderate-intensity activity.
Utilizing performance-based assessments to estimate functional capacity can play a
vital role in programs intended to elevate the health and well-being of LLA. Many of these
performance-based assessments are field tests, such as the 2MWT, which is designed to
utilize minimal equipment, take little time, and is easy to administer. While studies have
suggested the 2MWT is a good test of mobility and functional improvement [29,41], little
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has been done to quantify step counts and oxygen cost, which might be useful information
for practitioners or other researchers.
Participants in this study, identified as K3 ambulators, took 220.0 ± 24.3 steps over
147.02 ± 25.9 m during the 2MWT. Although this was farther than the 138 ± 28.5 m
walked in 70 recently reported K3 participants [41], the walking speed of our participants
aged 48.5 ± 14.8 years is comparable to LLA at ages up to 49 years (77.3 ± 14.8 m) and
50–59 years (74.5 ± 19.5 m) in the same study. While walking speeds of LLA vary greatly
across age, sex, amputation level, and duration of amputation, walking speeds in our study
were faster [51] and slower [52] than others.
Interestingly, there was no significant difference in the distance walked between sexes.
Although females took more steps than males (p = 0.034), resulting in significantly greater
cadence, this did not impact distance walked between sexes and is most likely due to
the shorter stature of females compared to males. This contrasts findings of others who
report faster walking speeds for males compared to females [29,41,53]. The resulting
similarity in VO2 and RPE between men and women suggests the same relative effort
during the 2MWT, thus supporting the finding of no difference in distance walked between
sexes. This could possibly be a function of the sample such that these male and female
participants were similar in mobility and fitness regardless of sex. The current study
included only K3 participants, and since studies have explored differences between sexes
without categorizing K levels [41,54], comparison across sexes cannot be fully detailed.
When comparing across amputation levels, the unilateral transfemoral group (UTF)
took approximately 25 fewer steps than the unilateral transtibial group (UTT). Although the
speed and distance walked were not significantly different between groups, the difference
in steps can be attributed to the trend of slower speeds, and less distance walked in UTF.
Previous studies have also reported slower speeds in this group compared to UTT [41].
Additionally, perceptual efforts were not different between groups, and while VO2 was not
significantly different, there was a trend for VO2 to be slightly higher in UTF, consistent with
other findings [55]. While these findings of metabolic and step data shed light on responses
during a 2MWT, this information raises further questions when drawing comparisons to
previous research. For example, the reason for limb loss [56], type of foot [57], or knee
used [58], and prostheses mass [59] are additional variables to consider when drawing
conclusions or categorizing performance while using tests such as the 2MWT.
Clinicians and practitioners may be interested in tracking steps in LLA as part of
improvement programs. Research-grade activity monitors may not be cost-effective for
most. Thus, consumer-grade monitors, such as the Garmin vivofit3, may offer a more
affordable alternative. Additionally, there may be a question as to where to place the
monitor for a better indicator of activity, such as on the wrist or the prosthesis. To identify
the most accurate activity monitor during the 2MWT, this study employed the Link and
StepWatch, typically used as research-grade monitors, and the vivofit3 as the consumer-
grade monitor.
The most accurate devices in this study were the StepWatch on the ankle (SA) and
the vivofit3 on the wrist (VW). These had the greatest agreement with actual steps taken
(AC) and the least amount of error, which was below 10% used by some [60] and below
3% recommended by others [61,62]. Our finding of SA accuracy during linear walking is
consistent with others [63,64], and the vivofit has been found to be more accurate at faster
walking speeds [27] than slower walking speeds [60,65]. It has been shown that error in
the vivofit is under 3% at slower walking speeds (53 m/min) and, therefore, a suitable
instrument to measure steps during free walking [66]. These authors also found error in
the vivofit to be under 1% at speeds of 80 m/min, which is close to the speeds walked and
error detected in our study.
Since it is designed to be worn on the wrist, error of the vivofit3 on the ankle (VA)
can be explained by its placement and, therefore, not recommended; however, error of the
Link on the wrist and ankle (LW and LA, respectively) is more difficult to interpret since
previous studies have found it to be accurate [67,68], while others found it to have a greater
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degree of error at various speeds [66,69]. Differences in findings may be explained by the
placement of the device, surface on which participants walk (over ground or treadmill),
sampling rate used (for example, 100 Hz as opposed to 50 Hz), population used (healthy,
neurological disorder, elderly, etc.), and adjusting the algorithms of the devices.
Participants were instructed to walk as fast and as safely as possible, and this was a
self-selected effort. Oxygen consumption during the 2MWT was 8.9 ± 2.9 mL/kg/min, and
RPE on Borg’s 6–20 scale was 10.1 ± 2.2 units. This approximates to 2.5 metabolic equivalent
of task (METs) and close to a perceived effort as “light”, respectively. Furthermore, HRs
during the 2MWT were 102.8 ± 19.4 b/min, and since Borg’s 6–20 scale was designed to
reflect HR for each rating point (a rating of 6 equates to 60 b/min, a rating of 20 equates to
200 b/min) [70], this further supports the light effort exerted by the participants. This is
below the “moderate” intensity of at least 3 METs and a rating of 12 (close to “somewhat
hard”) on Borg’s scale, which are suggested intensities for improvements in fitness [71].
The authors recognize that these metabolic values may not be steady-state, and should
participants continue to walk at this pace, VO2 may plateau at a slightly higher value. We
feel confident, however, that participants may not have been walking to the level of their
fitness due to their low perceived effort.
This brings to light that many participants may not be walking faster during the 2MWT
due to the limitation of their prostheses or because of the novelty of them performing the
test for the first time. Research often employs the 2MWT with a single trial as a means
to report functionality. However, these outcomes may be underreported if participants
are not truly walking as fast as they can. A previous report found that in a test–retest of
the 2MWT, distances walked on the second trial were significantly farther than the first
trial [29]. It was suggested this was not due to a learning effect since the practice was given
before testing began, nor was it due to a training effect since the duration between tests was
negligible. Metabolic and perceptual data in the current study indicate that participants
performing the 2MWT may self-select this as a light intensity task and thereby not walk as
fast as they can. Due to the lower MET values, it seems that fitness is not a limitation for
the 2MWT in K3 participants, and the limitation may simply be a lack of understanding
instructions, a perception of their own ability, or choice to walk only as fast as they are
comfortable with while wearing the prostheses.
Limitations
This study is not without its limitations, as we did not explore the role of etiology of
amputation on step and physiological variables. As prior scholarship has seen marked
differences in walking and physiological measures between dysvascular and traumatic
amputees [72], future studies should explore the role amputation etiology plays on the
studied variables. Our recruited participants are representative of a convenient sampling of
prosthesis users in our community, and future validation studies could perform an a priori
sample size estimation to ensure an adequately powered study. Moreover, prior scholarship
has observed that successive trials of the 2MWT can increase the distance walked [29].
We did not ask participants to perform multiple 2MWT trials, which may have produced
variability in walking distances. The decision not to recruit an able-bodied comparison
group, as well as not comparing the 2MWT to 6MWT, are limitations of this current study.
The type of prosthesis has been shown to influence step and physiological variables as
well. Our analysis did not investigate the role of foot, knee, or prosthetic suspension on
outcome measures. Future scholarship should investigate the aforementioned limitations
to elucidate further the relationship between amputation cause and prosthesis on step and
physiology during the 2MWT.
5. Conclusions
To the authors’ knowledge, this is the first study to report step count and metabolic
data in LLA K3 ambulators during the 2MWT, which could be useful information used
in rehabilitation objectives and prosthesis provision. Researchers, clinicians, practitioners,
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and others who may use this test should evaluate both walking and physiological measures
of their participants and clients to categorize them for mobility and functionality properly.
Furthermore, the SA and VW are reliable devices in measuring performance during this test
in this sample and, therefore, could be provided with treatment to track changes in cadence
and distance walked during the 2MWT across the continuum of prosthetic rehabilitation.
Author Contributions: Conceptualization, J.D.S. and G.G.; methodology, G.G. and J.D.S.; validation,
G.G.; formal analysis, J.D.S. and G.G.; investigation; J.D.S. and G.G.; resources, J.D.S.; data curation,
J.D.S. and G.G.; writing—original draft preparation, G.G. and J.D.S.; writing—review and editing,
J.D.S. and G.G.; visualization, J.D.S. and G.G.; supervision, J.D.S. and G.G.; project administration,
J.D.S. and G.G.; funding acquisition, J.D.S. All authors have read and agreed to the published version
of the manuscript.
Funding: This study was funded by the Texas A&M University-San Antonio Research Council and
College of Education and Human Development Faculty Grant Program.
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki, and approved by the Texas A&M University-San Antonio Institutional
Review Board (Log #2017-37).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Acknowledgments: The authors would like to thank Marcus Blaylock and Andrew Avila for their
help during data collection.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ziegler-Graham, K.; MacKenzie, E.J.; Ephraim, P.L.; Travison, T.G.; Brookmeyer, R. Estimating the Prevalence of Limb Loss in the
United States: 2005 to 2050. Arch. Phys. Med. Rehabil. 2008, 89, 422–429. [CrossRef]
2. Fortington, L.; Geertzen, J.; van Netten, J.; Postema, K.; Rommers, G.; Dijkstra, P. Short and Long Term Mortality Rates after a
Lower Limb Amputation. Eur. J. Vasc. Endovasc. Surg. 2013, 46, 124–131. [CrossRef]
3. Rowe, V.L.; Lee, W.; Weaver, F.A.; Etzioni, D. Patterns of treatment for peripheral arterial disease in the United States: 1996–2005.
J. Vasc. Surg. 2009, 49, 910–917. [CrossRef] [PubMed]
4. Narres, M.; Kvitkina, T.; Claessen, H.; Droste, S.; Schuster, B.; Morbach, S.; Rümenapf, G.; Van Acker, K.; Icks, A. Incidence of
lower extremity amputations in the diabetic compared with the non-diabetic population: A systematic review. PLoS ONE 2017,
12, e0182081. [CrossRef] [PubMed]
5. Pollmanns, J.; Weyermann, M.; Geraedts, M.; Drösler, S.E. Krankenhausfälle und Amputationen bei Diabetes mellitus-Zeitreihen
und Unterschiede auf kleinräumiger Ebene in Deutschland. Bundesgesundheitsblatt Gesundh. Gesundh. 2018, 61, 1462–1471.
[CrossRef] [PubMed]
6. Kurowski, J.R.; Nedkoff, L.; Schoen, D.E.; Knuiman, M.; Norman, P.E.; Briffa, T.G. Temporal trends in initial and recurrent lower
extremity amputations in people with and without diabetes in Western Australia from 2000 to 2010. Diabetes Res. Clin. Pract.
2015, 108, 280–287. [CrossRef]
7. Van Netten, J.J.; Sacco, I.C.; Lavery, L.A.; Monteiro-Soares, M.; Rasmussen, A.; Raspovic, A.; Bus, S.A. Treatment of modifiable
risk factors for foot ulceration in persons with diabetes: A systematic review. Diabetes/Metab. Res. Rev. 2020, 36, e3271. [CrossRef]
8. Thorud, J.C.; Plemmons, B.; Buckley, C.J.; Shibuya, N.; Jupiter, D.C. Mortality After Nontraumatic Major Amputation Among
Patients with Diabetes and Peripheral Vascular Disease: A Systematic Review. J. Foot Ankle Surg. 2016, 55, 591–599. [CrossRef]
9. Claessen, H.; Avalosse, H.; Van Hul, C.; Doggen, K.; Dumont, I.; Felix, P.; Van Acker, K.; Icks, A.; Guillaume, J.; Narres, M.; et al.
Decreasing rates of major lower-extremity amputation in people with diabetes but not in those without: A nationwide study in
Belgium. Diabetologia 2018, 61, 1966–1977. [CrossRef]
10. Webster, J.B.; Hakimi, K.N.; Williams, R.M.; Turner, A.P.; Norvell, D.C.; Czerniecki, J.M. Prosthetic fitting, use, and satisfaction
following lower-limb amputation: A prospective study. J. Rehabil. Res. Dev. 2012, 49, 1493. [CrossRef]
11. Pell, J.; Donnan, P.; Fowkes, F.; Ruckley, C. Quality of life following lower limb amputation for peripheral arterial disease. Eur. J.
Vasc. Surg. 1993, 7, 448–451. [CrossRef]
12. Davie-Smith, F.; Paul, L.; Nicholls, N.; Stuart, W.P.; Kennon, B. The impact of gender, level of amputation and diabetes on
prosthetic fit rates following major lower extremity amputation. Prosthet. Orthot. Int. 2017, 41, 19–25. [CrossRef]
13. Wurdeman, S.R.; Stevens, P.M.; Campbell, J.H. Mobility Analysis of AmpuTees (MAAT I). Prosthet. Orthot. Int. 2018, 42, 498–503.
[CrossRef]
14. Migaou, H.; Kalai, A.; Hassine, Y.H.; Jellad, A.; Boudokhane, S.; Frih, Z.B.S. Quality of Life Associated Factors in a North African
Sample of Lower Limbs Amputees. Ann. Rehabil. Med. 2019, 43, 321–327. [CrossRef]
Sensors 2021, 21, 2080 11 of 13
15. Boutwell, E.; Stine, R.; Hansen, A.; Tucker, K.; Gard, S. Effect of prosthetic gel liner thickness on gait biomechanics and pressure
distribution within the transtibial socket. J. Rehabil. Res. Dev. 2012, 49, 227–240. [CrossRef]
16. Klute, G.K.; Glaister, B.C.; Berge, J.S. Prosthetic liners for lower limb amputees: A review of the literature. Prosthet. Orthot. Int.
2010, 34, 146–153. [CrossRef] [PubMed]
17. Miyata, Y.; Sasaki, K.; Guerra, G.; Rattanakoch, J. Sustainable, affordable and functional: Reimagining prosthetic liners in resource
limited environments. Disabil. Rehabil. 2020, 1–7. [CrossRef] [PubMed]
18. Alley, R.D.; Williams, T.W., III; Albuquerque, M.J.; Altobelli, D.E. Prosthetic sockets stabilized by alternating areas of tissue
compression and release. J. Rehabil. Res. Dev. 2011, 48, 679–696. [CrossRef] [PubMed]
19. Paterno, L.; Ibrahimi, M.; Gruppioni, E.; Menciassi, A.; Ricotti, L. Sockets for Limb Prostheses: A Review of Existing Technologies
and Open Challenges. IEEE Trans. Biomed. Eng. 2018, 65, 1996–2010. [CrossRef]
20. Fatone, S.; Caldwell, R. Northwestern University Flexible Subischial Vacuum Socket for persons with transfemoral amputation—
Part 1. Prosthet. Orthot. Int. 2017, 41, 237–245. [CrossRef] [PubMed]
21. Ali, S.; Abu Osman, N.A.; Arifin, N.; Gholizadeh, H.; Razak, N.A.A.; Abas, W.A.B.W. Comparative Study between Dermo, Pelite,
and Seal-In X5 Liners: Effect on Patient’s Satisfaction and Perceived Problems. Sci. World J. 2014, 2014, 1–8. [CrossRef]
22. Gholizadeh, H.; Lemaire, E.; Eshraghi, A. The evidence-base for elevated vacuum in lower limb prosthetics: Literature review
and professional feedback. Clin. Biomech. 2016, 37, 108–116. [CrossRef] [PubMed]
23. Laschowski, B.; Andrysek, J. Electromechanical Design of Robotic Transfemoral Prostheses. In Proceedings of the ASME 2018
International Design Engineering Technical Conferences and Computers and Information in Engineering Conference, Quebec
City, QC, Canada, 2 November 2018; p. 5.
24. Endo, K.; Swart, E.; Herr, H. An artificial gastrocnemius for a transtibial prosthesis. In Proceedings of the 2009 Annual
International Conference of the IEEE Engineering in Medicine and Biology Society, Minneapolis, MN, USA, 2–6 September 2009;
pp. 5034–5037. [CrossRef]
25. Montgomery, J.R.; Grabowski, A.M. Use of a powered ankle–foot prosthesis reduces the metabolic cost of uphill walking and
improves leg work symmetry in people with transtibial amputations. J. R. Soc. Interface 2018, 15, 20180442. [CrossRef] [PubMed]
26. Gaunaurd, I.; Spaulding, S.E.; Amtmann, D.; Salem, R.; Gailey, R.; Morgan, S.J.; Hafner, B.J. Use of and confidence in administering
outcome measures among clinical prosthetists. Prosthet. Orthot. Int. 2015, 39, 314–321. [CrossRef]
27. Smith, J.D.; Guerra, G.; Burkholder, B.G. The validity and accuracy of wrist-worn activity monitors in lower-limb prosthesis users.
Disabil. Rehabil. 2019, 42, 3182–3188. [CrossRef]
28. Van Velzen, J.M.; Van Bennekom, C.A.M.; Polomski, W.; Slootman, J.R.; Van Der Woude, L.H.V.; Houdijk, H. Physical capacity
and walking ability after lower limb amputation: A systematic review. Clin. Rehabil. 2006, 20, 999–1016. [CrossRef] [PubMed]
29. Brooks, D.; Parsons, J.; Hunter, J.P.; Devlin, M.; Walker, J. The 2-minute walk test as a measure of functional improvement in
persons with lower limb amputation. Arch. Phys. Med. Rehabil. 2001, 82, 1478–1483. [CrossRef] [PubMed]
30. Resnik, L.; Borgia, M. Reliability of Outcome Measures for People with Lower-Limb Amputations: Distinguishing True Change
from Statistical Error. Phys. Ther. 2011, 91, 555–565. [CrossRef] [PubMed]
31. Paul, S.S.; Tiedemann, A.; Hassett, L.M.; Ramsay, E.; Kirkham, C.; Chagpar, S.; Sherrington, C. Validity of the Fitbitactivity tracker
for measuring steps in community-dwelling older adults. BMJ Open Sport Exerc. Med. 2015, 1, e000013. [CrossRef] [PubMed]
32. Fulk, G.D.; Combs, S.A.; Danks, K.A.; Nirider, C.D.; Raja, B.; Reisman, D.S. Accuracy of 2 Activity Monitors in Detecting Steps in
People with Stroke and Traumatic Brain Injury. Phys. Ther. 2014, 94, 222–229. [CrossRef]
33. Briseno, G.G.; Smith, J.D. Pedometer Accuracy in Persons Using Lower-Limb Prostheses. JPO J. Prosthet. Orthot. 2014, 26, 87–92.
[CrossRef]
34. Halsne, E.G.; Waddingham, M.G.; Hafner, B.J. Long-term activity in and among persons with transfemoral amputation. J. Rehabil.
Res. Dev. 2013, 50, 515–530. [CrossRef]
35. Chadwell, A.; Diment, L.; Micó-Amigo, M.; Ramírez, D.Z.M.; Dickinson, A.; Granat, M.; Kenney, L.; Kheng, S.; Sobuh, M.;
Ssekitoleko, R.; et al. Technology for monitoring everyday prosthesis use: A systematic review. J. Neuroeng. Rehabil. 2020, 17, 1–26.
[CrossRef]
36. Ladlow, P.; Nightingale, T.E.; McGuigan, M.P.; Bennett, A.N.; Phillip, R.; Bilzon, J.L.J. Impact of anatomical placement of an
accelerometer on prediction of physical activity energy expenditure in lower-limb amputees. PLoS ONE 2017, 12, e0185731.
[CrossRef]
37. Sears, T.; Avalos, E.; Lawson, S.; McAlister, I. Wrist-Worn Physical Activity Trackers Tend to Underestimate Steps During Walking.
Int. J. Exerc. Sci. 2017, 10, 764–773.
38. Reid, L.; Thomson, P.; Besemann, M.; Dudek, N. Going places: Does the two-minute walk test predict the six-minute walk test in
lower extremity amputees? J. Rehabil. Med. 2015, 47, 256–261. [CrossRef]
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